TargetRx, Shenzhen-based innovative drug development company, recently announced that it has completed a RMB150 million (US$21.2 million) Series A round financing, led by CCB Principal Capital Management, a fund under CCB International. Oriental Fortune Capital, Leaguer Tsing-Yuan Venture Capital and existing investor Shenzhen Capital Group also poured money into the new round. The proceeds raised […] Chinese New Drug Development Firm TargetRx Raises $21M In Series A Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.